Medications A (Avsola)
Fax Referral To: 1-888-280-1191 OR 787-759-4161

Phone: 1-888-280-1190 OR 787-759-4162

Email Referral To: Customer.ServiceFax@CVSHealth.com

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

		Six Simple Steps to Submitting a Referral		
PATIENT IN	FORMATION	(Complete or include demographic sheet)		
		DOB:		
Address:				
Gender: 🗌 Male				
Preferred Contac	ct Methods: 🗌	Phone (to primary # provided below) \square Text (to cell # provided below) \square Ema	ail (to email provided below)	
		r. If unable to contact via text or email, Specialty Pharmacy will attempt to contac		
Primary Phone: _		Alternate Phone:		
		rdian Name (Last, First):		
		Last Four of SSN: Primary Language: _		
PRESCRIBE	R INFORMAT	TION		
NPI #:	DEA #:	State License #: Group or Hospital:		
Address:		City, State, ZIP Code:Contact Person:Contact's P		
Phone:	Fax	Contact Person: Contact's P	hone:	
INSURANCE	EINFORMAT	ION Please fax copy of prescription and insurance cards with this form, if availa	able (front and back)	
		CAL INFORMATION	,	
Needs by Date:	AILD CEIMIC	Ship to: Patient Office Other	··	
Diagnosis (ICD:	-10).	Ship to Patient Office Other	•	
		mall Intestine Without Complications	testine Without Complications	
		mall & Large Intestine Without Complications	testine without complications	
		specified, Without Complications K51.00 Ulcerative (chronic) pancoli	tis without complications	
		ectosigmoiditis without complications		
_		pecified, without complications Other Code: Description	•	
Patient Clinical		Described, Without complications		
Allergies:		Weight:lb/kg Height:	in/cm	
B Test Result:				
		?		
		Last dose given: Next dose due:		
Nursing:				
	acy to coordina	te injection training/ home health infusion nurse visit necessary 🗌 Yes 🔲 No		
		fusion Clinic Outpatient Health Home Health		
		Date training occurred:		
		patient Pt already independent Referred by MD to alternate trainer		
Prescriber Phone		in the country in depondent in the country in the attention of the country in the		
PRESCRIPT		ATION		
MEDICATION		DOSE & DIRECTIONS	OUANTITY/REFILLS	
MEDICATION	STRENGTH			
		☐ Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse	IV at	
		5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter	Quantity:	
		Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg	# of 100 mg vial(s)	
		(Dose =mg) every 8 weeks	Refills:	
		☐ Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks	Kenus.	
Avsola	100 mg vial	n., .		
		Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse	ıv at	
	Ī	5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter		
		Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintenance Dose:		
		Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks		
		Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Other:		
Patient is interested		Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Other:	•	
	6 PRESCE	Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Other: Ograms	LOWED)	
DAW / May Not Sul	6 PRESCE ten" / Brand Medical bstitute	Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Other: Ograms	d/	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. Page 1 of 5

CVS specialty®

Medications C-H (Cimzia, Entyvio, Humira)

	Please Complete Par	tient and F	Prescriber Information	
Patient Name:		Patient DOB:		
Prescriber Name:			Prescriber Phone:	
Patient Clinical In			lh/kg Hoight	In/cm
Allergies: ΓΒ Test Result:			lb/kg Height:	In/Cm
	ON INFORMATION	ato		
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS
		Induction I	Dose: Inject SC 400 mg (2 injections) on day	Quantity: 1 kit
Cimzia	Cimzia Starter Kit (6 prefilled syringes)	1, and at w with 400 n	eeks 2 and 4. If response occurs, following every four weeks	(6 prefilled syringes) Refills: 0
Cimzia	200 mg/1 mL prefilled syringe 200 mg vial	Maintenan	oce <u>Dose</u> : Inject SC 400 mg ns) every 4 weeks	Quantity: Refills:
☐ Entyvio	300 mg in a single dose vial in individual carton	☐ Induction Dose: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then every 8 weeks thereafter ☐ Maintenance Dose: 300 mg infused IV over 30 minutes every 8 weeks ☐ Other:		Quantity: Refills:
☐ Humira	Adult Crohn's Disease/Ulcerative Colitis: PEN HUMIRA Starter Pack (CF) 80 mg/0.8 mL	Initial Dose: Inject SC 160 mg on Day 1, 80 mg on Day 15, then continue with maintenance dose starting Day 29 Inject SC 80 mg on Day 1, 80 mg on Day 2, 80 mg on Day 15, then continue with maintenance dose starting Day 29 Other:		Quantity: 1 kit (3 pens) Refills: 0
☐ Humira	Adult Crohn's Disease/Ulcerative Colitis: PEN HUMIRA (CF) 40 mg/0.4 mL SYRINGE HUMIRA (CF) 40 mg/0.4 mL PEN HUMIRA 40 mg/0.8 mL SYRINGE HUMIRA 40 mg/0.8 mL	Maintenance Dose: Inject SC 40 mg every other week Other:		Quantity: #2 (1 month) #6 (3 month) Refills:
Humira	17 kg (37 lbs) to less than 40 kg (88 lbs); ≥ 6 years: SYRINGE HUMIRA Starter Pack (CF) 80 mg/0.8 mL, 40 mg/0.4 mL	Pediatric Crohn's Disease Initial Dose: ☐ Inject SC 80 mg Day 1, then 40 mg Day 15, then continue with maintenance dose starting Day 29		Quantity: 1 kit (2 syringes) Refills: 0
☐ Humira	40 kg (88 lbs) and greater; ≥ 6 years: □ PEN HUMIRA Starter Pack (CF) 80 mg/0.8 ml □ SYRINGE HUMIRA Starter Pack (CF) 80 mg/0.8 mL □ PEN HUMIRA Starter Pack 40 mg/0.8 mL □ SYRINGE HUMIRA Starter Pack 40 mg/0.8 mL	Pediatric Crohn's Disease Initial Dose: Inject SC 160 mg Day 1, then 80 mg Day 15, then continue with maintenance dose starting Day 29 Inject SC 80 mg Day 1, 80 mg Day 2, 80 mg Day 15, then continue with maintenance dose starting Day 29 Other:		Quantity: QS Refills: 0
Humira	17 kg (37 lbs) to less than 40 kg (88 lbs); ≥ 6 years: SYRINGE HUMIRA (CF) 20 mg/0.2 mL	Pediatric Crohn's Disease Maintenance Dose: ☐ Inject SC 20 mg every other week ☐ Other:		Quantity: #2 (1 month) #6 (3 month) Refills:
Patient is interested in	patient support programs STAMP SIG PRESCRIBER SIGNATURE REQU	NATURE NOT AI		ided as needed for administration
DAW / May Not Subs Prescriber's Sig	n" / Brand Medically Necessary / Do Not Substitute / No Substitute gnature:Date: terchange is mandated unless Prescriber writes the words "No Su		May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: ATTN: New York and Iowa providers, p	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. ©2022 CVS Pharmacy, Inc. and one of its affiliates. 75-35829D 03/24/22 Page 2 of 5

Medications H-R (Humira, Inflectra, Infliximab, Remicade, Renflexis)

Dationt Name		Complete Patient and F			
Patient Name:			Patient DOB: Prescriber Phone:		
Prescriber Name: Patient Clinical In			Frescriber Friorie		
			lb/kg Height:	In/cm	
B Test Result:					
	ON INFORMATION				
MEDICATION	STRENGTH	DOS	E & DIRECTIONS	QUANTITY/REFILLS	
	40 kg (88 lbs) and greater;			Quantity:	
☐ Humira	≥ 6 years: ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL ☐ PEN HUMIRA 40 mg/0.8 mL ☐ SYRINGE HUMIRA 40 mg/0.8 mL	Pediatric Crohn's Disease M Inject SC 40 mg every o Other:	ther week	#2 (1 month) #6 (3 month) Refills:	
☐ Humira	20 kg (44 lbs) to less than 40 kg (88 lbs); ≥ 5 years: ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 40 mg/0.4 mL	Pediatric Ulcerative Colitis II Inject SC 80 mg Day 1, 4 continue with maintenance Other:	Quantity: 4 Pens/4 Prefilled syringes Refills: 0		
Humira	20 kg (44 lbs) to less than 40 kg (88 lbs); ≥ 5 years: ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ PEN HUMIRA (CF) 40 mg/0.4 mL ☐ SYRINGE HUMIRA (CF) 20 mg/0.2 mL	Pediatric Ulcerative Colitis Maintenance Dose: Inject SC 20 mg every week Inject SC 40 mg every other week Other:		Quantity: 1-month supply 3-month supply Refills:	
☐ Humira	40 kg (88 lbs) and greater; ≥5 years: □ PEN HUMIRA (CF) 80 mg/0.8 mL □ PEN HUMIRA (CF) 40 mg/0.4 mL □ SYRINGE HUMIRA (CF) 40 mg/0.4 mL	Pediatric Ulcerative Colitis Maintenance Dose: ☐ Inject SC 40 mg every week ☐ Inject SC 80 mg every other week ☐ Other:		Quantity: 1-month supply 3-month supply Refills:	
☐ Inflectra		☐ Crohn's Disease (Adult a Dose: Infuse IV at 5 mg/kg every 8 weeks thereafter ☐ Crohn's Disease (Adult)			
☐ Infliximab	100 mg vial	5-10 mg/kg (Dose =r Crohn's Disease (Pediati	Quantity: # of 100 mg vial(s)		
Remicade	, and the second	Ulcerative Colitis (Adult a Dose: Infuse IV at 5 mg/kg every 8 weeks thereafter	Refills:		
Renflexis		Ulcerative Colitis (Adult a Dose: Infuse IV at 5 mg/kg Other:			
			TAMP SIGNATURE NOT ALLO	rovided as needed for administratio	
"Dispense As Writter DAW / May Not Subs	n" / Brand Medically Necessary / Do No	t Substitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible		
	gnature:	Date:	Prescriber's Signature:	Date:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. ©2022 CVS Pharmacy, Inc. and one of its affiliates. 75-35829D 03/24/22

Medications R-Z (Rinvoq, Simponi, Stelara, Tysabri, Xeljanz, Zeposia)

Detient No.		Complete Patient and I		
			Patient DOB:	
Prescriber Name: Patient Clinical In			Prescriber Phone:	
			lb/kg Height:	ln/cm
TB Test Result:	vveignt.	Date:	lb/kg Height	
_	ON INFORMATION	Dutc		
MEDICATION	STRENGTH	DOSI	E & DIRECTIONS	QUANTITY/REFILLS
MEDICATION	STRENGTH	Induction Dose:	L & DIRLOTIONS	
Rinvoq	45 mg	Take 1 tablet once daily fo	or 8 weeks	Quantity: 1 btl = 28 Refill: 1
Rinvoq	☐ 15 mg ☐ 30 mg			Quantity: Refills:
Simponi	☐ 100 mg/mL in a single- dose prefilled SmartJect autoinjector ☐ 100 mg/mL in a single- dose prefilled syringe			Quantity: Refills:
☐ Stelara	130 mg/26 mL (5 mg/mL) IV single-dose vial Date Infusion was completed or scheduled: (This date is needed to determine shipment of Stelara SC maintenance dosage)	Single IV Induction Dose: 55 kg or less 260 mg at Week 0: # of vials to be used 2 more than 55 kg to 85 kg 390 mg at Week 0: # of vials to be used 3 more than 85 kg 520 mg at Week 0: # of vials to be used 4 Other:		Quantity: 2 Vials 3 Vials 4 Vials Refills: 0
Stelara	90 mg/mL SC dose in a single-dose prefilled syringe	90 mg SC dose 8 weeks after the initial IV induction dose, then every 8 weeks thereafter Other:		Quantity: Refills:
Tysabri	NA	Please complete a MS TOUCH/Tysabri enrollment form and indicate CVS/specialty as your preferred pharmacy provider. (For questions, please contact TOUCH Prescribing Program at 1-800-456-2255)		Quantity: 0 Refills: 0
☐ Xeljanz	☐ 5 mg ☐ 10 mg	☐ 10 mg twice daily for at least 8 weeks; followed by 5 or 10 mg twice daily, depending on therapeutic response. Use the lowest effective dose to maintain response. Discontinue Xeljanz after 16 weeks of treatment with 10 mg twice daily if adequate therapeutic benefit is not achieved. ☐ Other:		Quantity: Refills:
Zeposia	Starter Kit (4 capsules of 0.23 mg, 3 capsules of 0.46 mg and one bottle containing 30 capsules of 0.92 mg)	Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7, then take 0.92 mg capsule once daily starting on day 8)		Quantity: 37-day supply Refill: 0
Zeposia	7-Day Starter Pack (4 capsules of 0.23 mg and 3 capsules of 0.46 mg)	☐ Take 0.23 mg capsule once daily on days 1-4, followed by 0.46 mg capsule once daily on days 5-7		Quantity: 7-day supply Refill: 0
Zeposia	0.92 mg capsules	☐ Take 0.92 mg capsule once daily ☐ Other:		Quantity: Refills:
Patient is interested in	n patient support programs 6 PRESCRIBER SIGNA	STAMP SIGNATURE NOT A	Ancillary supplies and kits p FAMP SIGNATURE NOT ALLO	I rovided as needed for administration NED)
DAW / May Not Subs Prescriber's Sig	n" / Brand Medically Necessary / Do N	lot Substitute / No Substitution /Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

©2022 CVS Pharmacy, Inc. and one of its affiliates. 75-35829D 03/24/22

Page 4 of 5

Inflammatory Bowel Disease Enrollment Form Nursing Medications

			Prescriber Information		
atient Name:			Patient DOB:		
rescriber Name:			Prescriber Phone:		
<u>Patient Clinical Information:</u>			lh/ka Hoight:	In/om	
B Test Result:		Data:	lb/kg Height:		
PRESCRIPTION INFOR					
complete Items below, req	ivia i iOI1 iiiiad far Hama Inf	usion/Corom AIS:			
MEDICATION/SUPPLIES			TRENGTH/DIRECTIONS	QUANTITY/REFILLS	
MEDICATION/SUPPLIES	ROUTE			QUANTITY/REFILES	
Catheter PIV PORT PICC	IV	maintain IV access and p PIV – NS 5 mL (Heparin 10	0 units/mL 3-5 mL if multiple days) & Heparin 100 units/mL 3-5 mL,	Quantity: Refills:	
Hydration: NS D5W	IV	Pre: 500 mL 1000 mL Other: Concurrent: 500 mL 1000 mL Other: (Not to be infused using the same access as Ig) Post: 500 mL 1000 mL Other:		Hydration max infusion rate mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)	
Epinephrine **nursing requires**	□ IM □ SC	☐ Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) ☐ Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) ☐ Infant 0.1 mL/0.1 mL, 0.1 mL (7.5-15 kg/16.5-33 lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed		Quantity: Refills:	
☐ Diphenhydramine Oral	PO	Premedication 12.25 mg/kg (0-30 kg) 25 mg 50 mg (Over 30 kg) PRN severe allergic reaction – Call 911		Quantity: Refills:	
☐ Diphenhydramine 50 mg/mL vial	Slow IV	☐ 1 mg/kg (under 15 kg) ☐ 12.5-50 mg (15-30 kg) ☐ 25 mg ☐ 50 mg (Over 30 kg) PRN severe allergic reaction – Call 911 May repeat in 3-5 minutes as needed (Max dose-50 mg)		Quantity: Refills:	
☐ Flush Orders	Peripheral Access Central Venus Access	20 mL NS post flush 30 mL NS post flush		Send quantity sufficient for medication days supply	
Additional Medication:					
Patient is interested in patient support		STAMP SIGNATURE NOT A	Ancillary supplies and kits p	rovided as needed for administration	
"Dispense As Written" / Brand Medic DAW / May Not Substitute Prescriber's Signature :	cally Necessary / Do Not Si	ubstitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.